Supercharged proteins for cell penetration
First Claim
1. A supercharged protein associated with a functional peptide or protein, comprisinga supercharged protein havinga molecular weight of 4-100 kDa, a theoretical net charge of at least +10 at physiological pH, and a charge to molecular weight ratio of at least 0.8, wherein the supercharged protein is a supercharged protein variant of a wild-type protein and comprises a modified primary amino acid sequence as compared to the wild-type sequence,wherein the modified primary amino acid sequence comprises replacement of a plurality of charged or polar, solvent-exposed residues with a natural amino acid residue that is positively charged at physiological pH;
- anda functional peptide or protein selected from the group consisting of enzymes, DNA-binding proteins, histones, cytoskeletal proteins, receptor proteins, chaperone proteins, transcription factors, tumor suppressors, developmental regulators, growth factors, metastasis suppressors, pro-apoptotic proteins, and reprogramming factors,wherein the supercharged protein is covalently bound to the functional peptide or protein, and wherein the supercharged protein associated with the functional peptide or protein is able to penetrate a cell and deliver the functional peptide or protein to the cell.
5 Assignments
0 Petitions
Accused Products
Abstract
Compositions, preparations, systems, and related methods for delivering a supercharged protein, or a complex of a supercharged protein and an agent (e.g., nucleic acids, peptides, proteins, small molecules) to cells are provided. Such systems and methods include the use of supercharged proteins. For example, superpositively charged proteins may be associated with nucleic acids (which typically have a net negative charge) via electrostatic interactions. In some embodiments, such systems and methods involve altering the primary sequence of a protein in order to “supercharge” the protein (e.g., to generate a superpositively-charged protein). In some embodiments, complexes comprising supercharged proteins and one or more agents to be delivered are useful as therapeutic agents. In some embodiments, complexes and/or pharmaceutical compositions thereof are administered to a subject in need thereof. The inventive complexes or pharmaceutical compositions thereof may be used to treat proliferative diseases, infectious diseases, cardiovascular diseases, inborn errors in metabolism, genetic diseases, etc.
84 Citations
25 Claims
-
1. A supercharged protein associated with a functional peptide or protein, comprising
a supercharged protein having a molecular weight of 4-100 kDa, a theoretical net charge of at least +10 at physiological pH, and a charge to molecular weight ratio of at least 0.8, wherein the supercharged protein is a supercharged protein variant of a wild-type protein and comprises a modified primary amino acid sequence as compared to the wild-type sequence, wherein the modified primary amino acid sequence comprises replacement of a plurality of charged or polar, solvent-exposed residues with a natural amino acid residue that is positively charged at physiological pH; - and
a functional peptide or protein selected from the group consisting of enzymes, DNA-binding proteins, histones, cytoskeletal proteins, receptor proteins, chaperone proteins, transcription factors, tumor suppressors, developmental regulators, growth factors, metastasis suppressors, pro-apoptotic proteins, and reprogramming factors, wherein the supercharged protein is covalently bound to the functional peptide or protein, and wherein the supercharged protein associated with the functional peptide or protein is able to penetrate a cell and deliver the functional peptide or protein to the cell. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
- and
Specification